HLA<scp>‐G</scp> expression correlates with histological grade but not with prognosis in colorectal carcinoma

Kaprio, Tuomas; Sariola, Hannu; Linder, Nina; Lundin, Johan; Kere, Juha; Haglund, Caj; Wedenoja, Satu

doi:10.1111/tan.14334

Cited by 6 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Favoring HLA-G’s harmful impact on CRC patient prognosis, three studies have shown a significantly reduced OS (HR 3.14, p = 0.021; HR 0.311, p = 0.008 and HR 1.428, p = 0.044 respectively) in the HLA-G positive subgroup (Ye et al 2007 ; Guo et al 2015 ; Zhang et al 2017 ). On the other hand, three different studies did not identify any impact of HLA-G expression on patient prognosis (Fukushima et al 1998 ; Kaprio et al 2021 ; Zeestraten et al 2014 ). A peculiar finding was that of Reimers et al who demonstrated that patients with rectal cancer strongly expressing HLA-G showed prolonged DFS (HR 0.75; p = 0.042) compared to the 350 cases with a weak HLA-G expression (Reimers et al 2014 ).…”

Section: Resultsmentioning

confidence: 99%

“… 10% Zhang et al ( 2017 ) 457 I–IV 49% (NAT n.a.) Whole slide 4H84 > 5% 70.7% No impact OS > 55% 59.7% Negative impact Kaprio et al ( 2021 ) 307 I–IV 54% (NAT n.a.) TMA MAI-19219 n.a.…”

Section: Resultsmentioning

confidence: 99%

“…Due to this peculiar immune inhibitory function, HLA-G overexpression also represents a pivotal immune escape mechanism of several malignancies (Lin and Yan 2015 ; Murdaca et al 2018 ; Peng et al 2021 ; Rouas-Freiss et al 2014 ). However, contrasting data have been reported regarding the role of tumor cell HLA-G expression in the CRC setting (Fukushima et al 1998 ; Guo et al 2015 ; Kaprio et al 2021 ; Reimers et al 2014 ; Swets et al 2016 ; Ye et al 2007 ; Zeestraten et al 2013 ; Zhang et al 2017 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

HLA-G as a prognostic marker in stage II/III colorectal cancer: not quite there yet

Gambella

Scabini

Zoppoli

et al. 2022

Histochem Cell Biol

View full text Add to dashboard Cite

Identifying innovative molecules involved in the tumor immune escape process could help refine the survival stratification of colorectal cancer (CRC) patients. HLA-G, a non-classical HLA molecule, physiologically involved in tolerogenic mechanisms, has recently emerged as a relevant prognostic marker in other tumor types, but ambiguous data are reported in the CRC setting. This study aims to evaluate the HLA-G expression and prognostic potential in a series of stage II/III CRCs. HLA-G expression was evaluated in 100 pT3 CRC cases by means of immunohistochemistry using the 4H84 and MEM-G/2 monoclonal antibodies. We observed heterogeneous expression of HLA-G showing different ranges: 4H84 expression ranged from > 1 to 40%—median 7%; MEM-G/2 expression ranged from 20 to 90%—median 50%. HLA-G positivity (any intensity > 1%) varied according to the antibody employed, identifying: 8 4H84 positive, 34 MEM-G/2 positive, 6 double-positive and 52 negative cases. Correlation with clinico-pathologic data showed a significant association with a poor tumor differentiation in stage III right-sided CRC subgroup (p = 0.043), while no other pathologic variable was significantly associated. Survival analysis revealed a reduced disease-free survival rate (HR 4.304613; p = 0.031) in the subgroup of CRC-related death cases, while no correlations were observed considering the whole series and the overall survival. In conclusion, HLA-G is a promising CRC prognostic marker however much work is still required regarding technical aspects and evaluation of expression.

show abstract

Section: Resultsmentioning

confidence: 99%

“… 10% Zhang et al ( 2017 ) 457 I–IV 49% (NAT n.a.) Whole slide 4H84 > 5% 70.7% No impact OS > 55% 59.7% Negative impact Kaprio et al ( 2021 ) 307 I–IV 54% (NAT n.a.) TMA MAI-19219 n.a.…”

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HLA-G as a prognostic marker in stage II/III colorectal cancer: not quite there yet

Gambella

Scabini

Zoppoli

et al. 2022

Histochem Cell Biol

View full text Add to dashboard Cite

show abstract

“…In a different study, HLA-G expression in renal cancer tissue was demonstrated to be significantly higher than that in adjacent normal tissue, and the frequency of upregulated expression of HLA-G was significantly higher than that of other HLA antigens (72). HLA-G expression in patients with esophageal cancer, HCC and colorectal cancer has also been demonstrated to be significantly higher than that in healthy volunteers, and this was correlated with TNM stage, tumor histological grade, invasion degree, lymph node status and the immune response (73)(74)(75). The postoperative survival time of patients with HCC and with HLA-G + expression was significantly shorter than that of patients with HLA-Gexpression.…”

Section: Hla Polymorphism and Cancermentioning

confidence: 95%

Human leukocyte antigen and tumor immunotherapy (Review)

Liu

Mou²,

et al. 2023

Int J Oncol

View full text Add to dashboard Cite

Malignant tumors seriously endanger human health and life, and restrict economic development. Human leukocyte antigen (HLA) is the expression product of the human major histocompatibility complex, which, at present, is the most complex known polymorphic system. The polymorphism and expression of HLA molecules have been demonstrated to be associated with the occurrence and development of tumors. HLA molecules can regulate the proliferation of tumor cells and inhibit antitumor immunity. In the present review, the structure and function of HLA molecules, the polymorphism and expression of HLA in tumor tissue, the roles of HLA in tumor cells and tumor immunity, and the potential clinical application of HLA in tumor immunotherapy are summarized. The overall aim of the present review is to provide relevant information for the development of antitumor immunotherapies involving HLA in the clinic. Contents 1. Introduction 2. Physiological function and structure of HLA 3. HLA polymorphism and cancer 4. Function of HLA in tumor immunity 5. Clinical significance of HLA in tumor immunotherapy 6. Future perspectives

show abstract

“…This induces a transformation in macrophages towards the M2 phenotype (SPP1+ macrophages). SPP1+ macrophages attract regulatory T (Treg) and CD8+ T cells into CRC tissues, leading to anti-tumor immune resistance and depletion of CD8+ T cells (115,116).…”

Section: Human Leukocyte Antigen G and Ementioning

confidence: 99%

Pathways and molecules for overcoming immunotolerance in metastatic gastrointestinal tumors

Gan,

Li,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Worldwide, gastrointestinal (GI) cancer is recognized as one of the leading malignancies diagnosed in both genders, with mortality largely attributed to metastatic dissemination. It has been identified that in GI cancer, a variety of signaling pathways and key molecules are modified, leading to the emergence of an immunotolerance phenotype. Such modifications are pivotal in the malignancy’s evasion of immune detection. Thus, a thorough analysis of the pathways and molecules contributing to GI cancer’s immunotolerance is vital for advancing our comprehension and propelling the creation of efficacious pharmacological treatments. In response to this necessity, our review illuminates a selection of groundbreaking cellular signaling pathways associated with immunotolerance in GI cancer, including the Phosphoinositide 3-kinases/Akt, Janus kinase/Signal Transducer and Activator of Transcription 3, Nuclear Factor kappa-light-chain-enhancer of activated B cells, Transforming Growth Factor-beta/Smad, Notch, Programmed Death-1/Programmed Death-Ligand 1, and Wingless and INT-1/beta-catenin-Interleukin 10. Additionally, we examine an array of pertinent molecules like Indoleamine-pyrrole 2,3-dioxygenase, Human Leukocyte Antigen G/E, Glycoprotein A Repetitions Predominant, Clever-1, Interferon regulatory factor 8/Osteopontin, T-cell immunoglobulin and mucin-domain containing-3, Carcinoembryonic antigen-related cell adhesion molecule 1, Cell division control protein 42 homolog, and caspases-1 and -12.

show abstract

HLA‐G expression correlates with histological grade but not with prognosis in colorectal carcinoma

Cited by 6 publications

References 25 publications

HLA-G as a prognostic marker in stage II/III colorectal cancer: not quite there yet

HLA-G as a prognostic marker in stage II/III colorectal cancer: not quite there yet

Human leukocyte antigen and tumor immunotherapy (Review)

Pathways and molecules for overcoming immunotolerance in metastatic gastrointestinal tumors

Contact Info

Product

Resources

About